Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer

Expert Opin Drug Deliv. 2024 Feb;21(2):309-324. doi: 10.1080/17425247.2024.2311812. Epub 2024 Jan 31.

Abstract

Introduction: The resistance to chemotherapy is a significant hurdle in breast cancer treatment, prompting the exploration of innovative strategies. This review discusses the potential of dual-loaded liposomal carriers to combat chemoresistance and improve outcomes for breast cancer patients.

Areas covered: This review discusses breast cancer chemotherapy resistance and dual-loaded liposomal carriers. Drug efflux pumps, DNA repair pathways, and signaling alterations are discussed as chemoresistance mechanisms. Liposomes can encapsulate several medicines and cargo kinds, according to the review. It examines how these carriers improve medication delivery, cancer cell targeting, and tumor microenvironment regulation. Also examined are dual-loaded liposomal carrier improvement challenges and techniques.

Expert opinion: The use of dual-loaded liposomal carriers represents a promising and innovative strategy in the battle against chemotherapy resistance in breast cancer. This article has explored the various mechanisms of chemoresistance in breast cancer, emphasizing the potential of dual-loaded liposomal carriers to overcome these challenges. These carriers offer versatility, enabling the encapsulation and precise targeting of multiple drugs with different modes of action, a crucial advantage when dealing with the complexity of breast cancer treatment.

Keywords: Chemotherapy; immunomodulators; liposomes; nanocarriers; resistance.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Drug Carriers / therapeutic use
  • Drug Delivery Systems / methods
  • Female
  • Humans
  • Liposomes
  • Tumor Microenvironment

Substances

  • Liposomes
  • Antineoplastic Agents
  • Drug Carriers